4BIO Capital leads Redpin Therapeutics’ $15.5 million Series A

4BIO Capital appoints Philippe Fauchet, OBE, as Venture Partner, Japan

4BIO Capital raises $50 million in first close of new advanced therapies fund

Spark Therapeutics enters into definitive merger agreement with Roche

4BIO portfolio company Orchard Therapeutics announces ADA-SCID follow-on results

EGLSF I wins two EuroHedge Emerging Fund Management Awards